Systemic Anti-Cancer Therapy Regimen Library
SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk]
Treatment Overview
Exact scheduling of cycles is dependent on type of local therapy (e.g. radiation therapy) and when it is given.
The General Treatment schema is below, refer to the individual patient's individual treatment plan for details.
As a 3-week cycle for cycles 1 and 9 (refer Treatment Schema above), or as per patient's individual treatment plan.
As a 3-week cycle for cycles 2, 10, 19 and 20 (refer Treatment Schema above), or as per patient's individual treatment plan.
As a 2-week cycle for cycles 3, 5, 7 and 12 (refer Treatment Schema above), or as per patient's individual treatment plan.
As a 2-week cycle for cycles 4, 6, 11 and 13 (refer Treatment Schema), or as per patient's individual treatment plan.
As a 3-week cycle for cycle 8 (refer Treatment Schema), or as per patient's individual treatment plan.
As a 3-week cycle for cycle 14 (refer Treatment Schema above), or as per patient's individual treatment plan.
As a 3-week cycle for cycles 15, 16, and 18 (refer Treatment Schema above), or as per patient's individual treatment plan.
As 3-week cycle for cycle 17 (refer Treatment Schema above), or as per patient's individual treatment plan.
Supportive Care Factors
| Factor | Value |
|---|---|
| Constipation risk: | Variable |
| Diarrhoea risk: | Variable |
| Emetogenicity: | Variable |
| Growth factor support: | Variable |
| Hydration: | Variable |
| Mesna uroprotection: | Variable |
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.